Treats elevated intraocular pressure. ANDA 90143, held by Bausch & Lomb. Dorzolamide Hydrochloride.
As of Nov 21, 2026, ANDA 90143 (Dorzolamide Hydrochloride), held by Bausch & Lomb, was first approved by FDA on Jun 25, 2009, with 1 approved supplement and 0 published complete response letters.
Dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide hydrochloride ophthalmic solution is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dorzolamide HydrochlorideEQ 2% BASE · solution/drops;ophthalmic | Dorzolamide Hydrochloride | Rx |
| Feb 20, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 25, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters